Subsidiary Of Zydus Pharma Gets USFDA Approval For Nystatin Topical Powder

Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA, has received final approval from the USFDA to market Nystatin Topical Powder USP, 100,000 units per gram, Cadila Healthcare informed the bourses on Saturday.

Nystatin Topical Powder is an antifungal antibiotic used to treat skin infections caused by yeast.

Meanwhile, Cadila Healthcare was up by 1% at Rs 546.45 per share at 0923 hours IST on BSE. It hit a high of Rs 549 and a low of Rs 545.15 in the morning session.

The stock has delivered more than 70% returns over a period of 1 year. It has outperformed BSE Sensex and BSE Healthcare over the same period.

Zydus Group firm Cadila Healthcare Limited is a well-known research-oriented, technology-driven pharmaceutical company focused on the research areas of biotechnology, formulations and Active Pharmaceutical Ingredients.

or Quick Trial – 8962000225 ✔ 
or mail us here:
or visit
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.